CellCentric

Cellcentric email format

Verified email-pattern data for Cellcentric is currently limited. You can still use the company insights and contact sections below.
Inobrodib is the first small molecule drug in the clinic targeting twin proteins p300 and CBP. It is formulated as a capsule taken orally. p300/CBP are twin (paralogue) acetyl transferases, and importantly, gene activating proteins that are known to play an important role in the progression of certain cancers. CellCentric’s pioneering drug is in Phase I/II clinical trials to evaluate its effectiveness to treat specific solid tumours, as well as haematological malignancies (blood cancers). These represent major clinical unmet needs, delivering a new therapy for people with cancer, who otherwise have few alternatives.

Company Details

Employees
46
Address
Chesterford Research Park, Little Chesterford,united Kingdom
Industry
Biotechnology
Keywords
Oxford.
HQ
Cambridge
Looking for a particular CellCentric employee's phone or email?

Cellcentric Questions

Explore related pages

Related company profiles:

Top CellCentric Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant